Thermo Fisher Scientific (TMO) : Alta Capital Management reduced its stake in Thermo Fisher Scientific by 1.14% during the most recent quarter end. The investment management company now holds a total of 282,351 shares of Thermo Fisher Scientific which is valued at $42,925,823 after selling 3,262 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Thermo Fisher Scientific makes up approximately 2.71% of Alta Capital Management’s portfolio.
Other Hedge Funds, Including , Banced Corp reduced its stake in TMO by selling 481 shares or 14.66% in the most recent quarter. The Hedge Fund company now holds 2,799 shares of TMO which is valued at $433,565. Thermo Fisher Scientific makes up approx 0.86% of Banced Corp’s portfolio.Bristlecone Advisors reduced its stake in TMO by selling 500 shares or 9.08% in the most recent quarter. The Hedge Fund company now holds 5,005 shares of TMO which is valued at $775,275. Thermo Fisher Scientific makes up approx 0.28% of Bristlecone Advisors’s portfolio.North Star Asset Management Inc reduced its stake in TMO by selling 828 shares or 1.81% in the most recent quarter. The Hedge Fund company now holds 44,964 shares of TMO which is valued at $7,116,902. Thermo Fisher Scientific makes up approx 0.80% of North Star Asset Management Inc’s portfolio.Franklin Street Advisors Inc Nc reduced its stake in TMO by selling 5,035 shares or 20.14% in the most recent quarter. The Hedge Fund company now holds 19,961 shares of TMO which is valued at $3,159,427. Thermo Fisher Scientific makes up approx 0.58% of Franklin Street Advisors Inc Nc’s portfolio.
Thermo Fisher Scientific closed down -4.21 points or -2.65% at $154.9 with 26,97,528 shares getting traded on Tuesday. Post opening the session at $156, the shares hit an intraday low of $153.79 and an intraday high of $156.585 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $2.01. The company had revenue of $4535.20 million for the quarter, compared to analysts expectations of $4493.28 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.